TITLE

Soluble ST2 Plasma Concentrations Predict Mortality in HBV-Related Acute-on-Chronic Liver Failure

AUTHOR(S)
Lei, Ziying; Mo, Zhishuo; Zhu, Jianyun; Pang, Xiuqing; Zheng, Xingrong; Wu, Zhebin; Wang, Ke; Li, Xinhua; Xie, Dongying; Gao, Zhiliang
PUB. DATE
March 2015
SOURCE
Mediators of Inflammation;3/29/2015, Vol. 2015, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a rapidly progressing and frequently fatal condition. The aim of this study was to determine whether interleukin- (IL-) 33 and soluble ST2 (sST2) were associated with disease severity and mortality in HBV-ACLF. We found that plasma levels of sST2 but not IL-33 were higher in HBV-ACLF patients compared with chronic hepatitis B (CHB) patients and healthy controls. However, plasma levels of IL-33, TNF-α, IFN-γ, and IL-10 did not correlate with sST2 levels. Similarly, immunohistochemistry revealed low IL-33 expression and high ST2 expression in liver sections of patients with HBV-ACLF. Evaluation of dynamic changes of sST2 in HBV-ACLF showed that plasma sST2 levels increased over time in patients who died during the 180-day follow-up but decreased in those who survived. In addition, plasma sST2 level after week 1 correlated with disease severity, as assessed by total bilirubin, prothrombin time, and model for end-stage liver disease score. Results of Kaplan-Meier survival analysis showed that higher sST2 concentration (≥87 ng/mL) at week 3 was associated with poor survival. These findings indicate the potential usefulness of sST2 as a predictor of disease severity and in making treatment decisions for patients with HBV-ACLF.
ACCESSION #
109224138

 

Related Articles

  • Serum miR-181b Is Correlated with Hepatitis B Virus Replication and Disease Progression in Chronic Hepatitis B Patients. Yu, Fujun; Zhou, Guangyao; Li, Guojun; Chen, Bicheng; Dong, Peihong; Zheng, Jianjian // Digestive Diseases & Sciences;Aug2015, Vol. 60 Issue 8, p2346 

    Background: Previously, we reported that microRNA-181b (miR-181b) activates hepatic stellate cells partly through the phosphatase and tensin homolog deleted on chromosome 10 (PTEN)/Akt pathway. Aims: The main objective of this study was to ascertain whether serum miR-181b expression is...

  • Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. Ahn, Jem Ma; Sinn, Dong Hyun; Gwak, Geum-Youn; Paik, Yong-Han; Choi, Moon Seok; Lee, Joon Hyeok; Koh, Kwang Cheol; Paik, Seung Woon // PLoS ONE;12/22/2015, Vol. 10 Issue 12, p1 

    Objectives: We investigated whether long-term clinical outcomes such as disease progression or inactive hepatitis B virus (HBV) carrier state can be predicted by baseline factors in hepatitis B e antigen (HBeAg)-negative HBV infected patients with an elevated viral load. Methods: A...

  • Serum proteomics analysis and comparisons using iTRAQ in the progression of hepatitis B. LIANG PENG; JING LIU; YANG-MEI LI; ZHAN-LIAN HUANG; PEI-PEI WANG; YU-RONG GU; YU-BAO ZHENG; ZHI-LIANG GAO // Experimental & Therapeutic Medicine;2013, Vol. 6 Issue 5, p1169 

    The aim of this study was to analyze the changes in serum protein levels in the progression of hepatitis B using isobaric tags for relative and absolute quantitation (iTRAQ) analysis, in addition to comparing the serum protein levels of patients with chronic hepatitis B (CHB), patients with...

  • Improving the identification of priority populations to increase hepatitis B testing rates, 2012. van Gemert, Caroline; Julie Wang; Simmons, Jody; Cowie, Benjamin; Boyle, Douglas; Stoove, Mark; Enright, Chris; Hellard, Margaret; Wang, Julie // BMC Public Health;2/1/2016, Vol. 16 Issue 1, p1 

    Background: It is estimated that over 40 % of the 218,000 people with chronic hepatitis B (CHB) in Australia in 2011 are undiagnosed. A disproportionate number of those with undiagnosed infection were born in the Asia-Pacific region. Undiagnosed CHB can lead to ongoing transmission...

  • Up-regulation of IL-12 expression in patients with chronic hepatitis B is mediated by the PI3K/Akt pathway. Wang, Hong-wei; Gao, Hai-li; Wei, Xiao-xia; Wang, Xin-hong // Molecular & Cellular Biochemistry;Sep2015, Vol. 407 Issue 1/2, p135 

    Hepatitis B virus (HBV) replicates noncytopathically in hepatocytes, but HBV or proteins encoded by HBV genome could induce cytokines, chemokines expression by hepatocytes.IL-12 is a typical proinflammatory cytokine that plays a critical role in host defense against pathogens, including the HBV....

  • Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. Tsuge, Masataka; Murakami, Eisuke; Imamura, Michio; Abe, Hiromi; Miki, Daiki; Hiraga, Nobuhiko; Takahashi, Shoichi; Ochi, Hidenori; Nelson Hayes, C.; Ginba, Hiroyuki; Matsuyama, Kazuhiro; Kawakami, Hiroiku; Chayama, Kazuaki // Journal of Gastroenterology;Oct2013, Vol. 48 Issue 10, p1188 

    Background: Treatment for chronic hepatitis B has improved drastically with the use of nucleot(s)ide analogues (NAs). However, NA therapy typically fails to eliminate Hepatitis B virus (HBV) completely, and it is difficult to discontinue these therapies. We previously demonstrated that NA...

  • Molecular characterization of hepatitis B virus X gene in chronic hepatitis B patients. Luciana Barbini; Luciana Tadey; Silvina Fernandez; Belen Bouzas; Rodolfo Campos // Virology Journal;2012, Vol. 9 Issue 1, p131 

    Background: HBV-X protein is associated with the pathogenesis of HBV related diseases, specially in hepatocellular carcinomas of chronic patients. Genetic variability of the X gene includes genotypic specific variations and mutations emerging during chronic infection. Its coding sequence...

  • Association between Serum Concentrations of HBV-DNA and HBeAg with Liver Enzymes in Hepatitis B Patients. Babamahmoodi, Farhang; Farokhee, Maryam; Delavarian, Leila; Babamahmoodi, Abdolreza; Khalilian, Alireza; Haghshenas, Mohammad Reza // Journal of Mazandaran University of Medical Sciences (JMUMS);Dec2012, Vol. 22 Issue 95, p1 

    Background and purpose: Hepatitis B virus (HBV) is a major global health problem. The prevalence of HBV infection varies throughout regions of the world. More than 350 million people live with chronic HBV infection and many different clinical symptoms are associated with it. Long-term...

  • Effect of pegylated interferon α-2a combined with thymosin α1 on quality of life in patients with chronic hepatitis B. LU Jianguo // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;dec2013, Vol. 29 Issue 12, p922 

    Obj'ective To investigate the effect of pegylated interferon α - 2a ( PEG - IFN α - 2a) combined with thymosin α1 ( Tα1 ) on the quality of life ( QOL) in patients with chronic hepatitis B ( CHB) . Methods A total of 148 patients with CHB who were admitted to our department from...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics